3 recruiting, 1 completed, 1 unknown, 1 withdrawn. 2 Not applicable, 2 Phase 1, 1 Phase 2, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Recruiting 2 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
| Phase 4 | 1 | Recruiting 1 |
Follow Type 2 Diabetes Patients: new trials by email Literature Review of Type 2 Diabetes Patients trials Research Report on Type 2 Diabetes Patients
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin hepalatide - Type 2 Diabetes Patients | Phase 1 / Phase 2 | Withdrawn | Shanghai HEP Pharmaceutical Co., Ltd. | 2025-12-01 | 2023-12-08 | |
| Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients Plasmatic PPi level - Type 2 Diabetes, Type 2 Diabetes Patients | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 20 | 2025-06-18 | 2025-07-10 |
| The Effect of Education Given to Type 2 Diabetics on Diabetes Self-management, Health Fatalism and Metabolic Parameters Experimental Group - Type 2 Diabetes, Type 2 Diabetes Patients | Not applicable | Recruiting | Ataturk University | 66 | 2025-02-01 | 2025-02-25 |
| Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD) Liraglutide, insulin glargine - Type 2 Diabetes Patients, Overweight and Obesity | Phase 4 | Recruiting | The First Affiliated Hospital of Xiamen University | 164 | 2019-01-10 | 2025-01-13 |
| Attachment Style of Type 2 Diabetics, and Cognitive, Social and Emotional Variables as Explanatory Factors of Adherence to Self-care Behavior and Diabetes Control questionnaire - Type 2 Diabetes Patients | Unknown | Assuta Hospital Systems | 300 | 2011-08-01 | 2012-05-01 | |
| A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients PF-04620110, Placebo - Type 2 Diabetes Patients | Phase 1 | Completed | Pfizer | 48 | 2011-02-01 | 2012-11-06 |
Diabetes Mellitus, Type 2 (2) · Hyperglycemia (1) · Obesity (1) · Overweight (1)
Glucose Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Diabetes Mellitus (2) · Endocrine System Diseases (2) · Body Weight (1) · Nutrition Disorders (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Insulin Glargine (1) · Liraglutide (1) · PF-04620110 (1) · Surveys and Questionnaires (1)
Assuta Hospital Systems (1) · Ataturk University (1) · Centre Hospitalier Universitaire de Nice (1) · Pfizer (1) · Shanghai HEP Pharmaceutical Co., Ltd. (1) · The First Affiliated Hospital of Xiamen University (1)
China (1) · France (1) · Israel (1) · Turkey (Türkiye) (1) · United States (1)
Xuejun Li, MD (1)